Monthly Archives: October 2008

Distractions Abound – DTC Perspectives Day 2

By Andy Levitt | Published: October 31, 2008
Andy Levitt of HealthTalker checks in with a report from day 2 of the DTC Perspectives conference in New Jersey. I had to laugh. And you would, too. I looked around the room as the clock approached noon today during Day 2 of the Fall DTC Perspectives conference. I was amazed by the amount of distraction that [...]
Posted in Advertising, E-Media, Events | Tagged , , , , , , | 1 Comment

Eliminate Waste (Whatever That Is)

By Patrick Clinton | Published: October 30, 2008
There’s a fascinating editorial in this week’s New England Journal of Medicine by Henry J. Aaron, a healthcare economist at the Brookings Institution. Aaron argues that on average healtchare spending is not wasteful, since its benefits exceed its costs. But that doesn’t mean there isn’t waste. The trick, though, is to identify it, and as [...]
Posted in Uncategorized | Tagged , , , | Leave a comment

Blind Ambition – DTC Perspectives Day 1

By Andy Levitt | Published: October 30, 2008
HealthTalker CEO Andy Levitt continues his trek across the US, hitting a slew of pharma meetings and speaking at a handful of them. Here’s his wrap up of the DTC Perspectives conference in Livingston, New Jersey. The pharma Fall conference season is in full swing, and today I am happy to be in New Jersey to [...]
Posted in Advertising, E-Media, Events | Tagged , , , , , , | 4 Comments

Pfizer Responds to Adverse Events Report

By George Koroneos | Published: October 29, 2008
A report released last week by the The Institute for Safe Medication Practices (and covered yesterday on PharmExec.com), listed Pfizer’s smoking cessation drug Chantix as the number one most reported drug for adverse reactions in the first quarter of 2008. The report states that FDA received 1,001 reports of serious side effects for varenicline (the generic [...]
Posted in Safety | Tagged , , , , , , | 2 Comments

Heat From FDAAA: Time For New GPP

By Joanna Breitstein | Published: October 29, 2008
Good Publication Practice, or GPP, is often the first port-of-call for companies publishing in the biomedical sector. But consider this. The first ideas for GPP were formed a decade ago, and now the time is right for GPP2: the new, revised Good Publication Practice. Why now? Pharma publication practice is a hot potato. Purported cases of publication-related [...]
Posted in Regulatory | Tagged , , , , , , , | Leave a comment